Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment

被引：0
|
作者：
Wang, Jaw-Yuan
Tsai, Hsiang-Lin
Sung, Yung-Chuan
机构：
[1] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan
[2] Kaohsiung Med Univ, Chung Ho Mem Hosp, Dept Surg, Div Colorectal Surg, Kaohsiung, Taiwan
[3] Cathay Gen Hosp, Div Hematol Oncol, Dept Internal Med, Taipei, Taiwan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
208
引用
收藏
页数：2
相关论文
共 50 条
  • [31] SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients
    Mei, Zhu
    Shao, Yang W.
    Lin, Peinan
    Cai, Xiaomin
    Wang, Biao
    Ding, Yan
    Ma, Xiangyuan
    Wu, Xue
    Xia, Yewei
    Zhu, Dongqin
    Shu, Yongqian
    Fu, Zan
    Gu, Yanhong
    BMC CANCER, 2018, 18
  • [32] Cetuximab - In the treatment of metastatic colorectal cancer
    Reynolds, NA
    Wagstaff, AJ
    DRUGS, 2004, 64 (01) : 109 - 118
  • [33] Cetuximab for treatment of metastatic colorectal cancer
    Cerea, G.
    Ricotta, R.
    Schiavetto, I.
    Maugeri, M. R.
    Sartore-Bianchi, A.
    Moroni, M.
    Artale, S.
    Siena, S.
    ANNALS OF ONCOLOGY, 2006, 17 : VII66 - VII67
  • [34] Cetuximab in the treatment of metastatic colorectal cancer
    Moosmann, Nicolas
    Heinemann, Volker
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2007, 7 (02) : 243 - 256
  • [35] Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy
    Nemecek, Radim
    Berkovcova, Jitka
    Radova, Lenka
    Kazda, Tomas
    Mlcochova, Jitka
    Vychytilova-Faltejskova, Petra
    Slaby, Ondrej
    Svoboda, Marek
    ONCOTARGETS AND THERAPY, 2016, 9 : 4695 - 4703
  • [36] First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer
    Uemura, Mamoru
    Kim, Ho Min
    Hata, Tsuyoshi
    Sakata, Kazuya
    Okuyama, Masaki
    Takemoto, Hiroyoshi
    Fujii, Hitoshi
    Fukuzaki, Takayuki
    Morita, Tetsushi
    Hata, Taishi
    Takemasa, Ichiro
    Satoh, Taroh
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Mori, Maski
    MOLECULAR AND CLINICAL ONCOLOGY, 2016, 5 (02) : 375 - 379
  • [37] First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer
    Ohta, Katsuya
    Ikenaga, Masakazu
    Uemura, Mamoru
    Sakata, Kazuya
    Nishimura, Junichi
    Hata, Taishi
    Matsuda, Chu
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Mori, Masaki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 216 - 216
  • [38] Cetuximab-Based Treatment of Metastatic Anal Cancer: Correlation of Response with KRAS Mutational Status
    Lukan, Nadine
    Stroebel, Philipp
    Willer, Andreas
    Kripp, Melanie
    Dinter, Dietmar
    Mai, Sabine
    Hochhaus, Andreas
    Hofheinz, Ralf-Dieter
    ONCOLOGY, 2009, 77 (05) : 293 - 299
  • [39] The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study
    Tsai, Hsiang-Lin
    Lin, Chun-Chi
    Sung, Yung-Chung
    Chen, Shang-Hung
    Chen, Li-Tzong
    Jiang, Jeng-Kai
    Wang, Jaw-Yuan
    BRITISH JOURNAL OF CANCER, 2023, 129 (06) : 947 - 955
  • [40] Atypical RAS Mutations in Metastatic Colorectal Cancer
    Pietrantonio, Filippo
    Yaeger, Rona
    Schrock, Alexa B.
    Randon, Giovanni
    Romero-Cordoba, Sandra
    Rossini, Daniele
    Fuca, Giovanni
    Ross, Jeffrey S.
    Kotani, Daisuke
    Madison, Russell
    Kim, Seung Tae
    Salvatore, Lisa
    Raimondi, Alessandra
    Pagani, Filippo
    Borelli, Beatrice
    Perrone, Federica
    Di Bartolomeo, Maria
    Miller, Vincent A.
    Ali, Siraj M.
    Lee, Jeeyun
    Yoshino, Takayuki
    de Braud, Filippo
    Falcone, Alfredo
    Hechtman, Jaclyn F.
    Cremolini, Chiara
    JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 11
12345